Files
Abstract
Human norovirus (HuNoV) is a principal cause of acute gastroenteritis. Its global prevalence is underscored by ~700 million infections and >200,000 deaths annually. Currently there are no licensed vaccines or therapeutics to lessen HuNoV disease burden. Vaccine options are limited to recombinant approaches because a vaccine-approved cell substrate has not been shown to support HuNoV. Vero cells have been used extensively as a viral vaccine cell substrate because of their deficiency in interferon responsiveness. In these studies, HuNoV replication in Vero cells was examined, host-targeted strategies evaluated, and exosome-mediated HuNoV infection assessed to improve HuNoV replication. These studies provide support for use of Vero cells as a platform-enabling technology for HuNoV vaccine development.